![Compass](/-/media/williamblairwebsite/feature/heros/generic-heros/trends-perspectives_hero_2048x1360.jpg?cx=0.3130194&cy=-0.140625&cw=800&ch=571&hash=7109A97C43CF04C9B08F477F60CD11C6)
William Blair Thinking
-
-
We’re on IT: Navigating 2025’s Dynamic IT Services Landscape
In this episode of William Blair Thinking Presents, technology analyst Maggie Nolan, partner, CPA, dives into the latest trends in IT services, exploring the impact of generative AI, data infrastructure, and political influences on the industry.
-
Our Mission, Vision, and Values
At William Blair, we're committed to our colleagues, our clients, and our communities. Serving our clients starts with the capabilities and collaboration of our team—making our employees our most important asset. When we create an environment where employees perform their best, our delivery for clients will be the best it can be.
Learn more about our mission, vision, and values![](/-/media/williamblairwebsite/feature/heros/generic-heros/mvv_page_header_2048x1360.jpg?la=en&h=1360&w=2048&hash=DA44066DF17A8BB35CEE69F91D39E15B)
Global Community Partners
We are proud of our signature Global Community Partners program, through which employees nominate organizations to receive catalytic financial support and significant volunteerism opportunities every two years.
More about our community partnersOur Latest News
-
-
Rubrik, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Rubrik, Inc. (RBRK $75.59), a leading vendor in the fast-evolving data protection (DP) industry, pioneering a next-generation approach to data backup and transforming perceptions of DP technology from “boring old backup” to a must-have cyber resilience platform.
-
Mersana Therapeutics, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Mersana Therapeutics, Inc. (MRSN $0.57), whose lead program emiltatug ledadotin is an ADC that targets B7-H4; it is in Phase I development for TNBC. The company is also developing a HER2-targeted immune-stimulating ADC, XMT-2056, in a Phase I solid tumor study.
Join Our Team
Finding, attracting, and developing talented people is the foundation of our success. Learn about the promising career opportunities currently available at William Blair.
Search our job openings![Women sitting outside with a laptop](/-/media/williamblairwebsite/feature/promo-banner/join-our-team_feature_2048x1360.jpg?la=en&h=1360&w=2048&hash=0AEF5A022F15A1CAD26032704561DCB3)
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights